Dr. Serafino Pantano has several years of experience in Translational Science, Biomarkers and Diagnostics, and he is currently Biomarker and Diagnostics Leader for the EMEAC region in Merck, Sharp & Dohme (MSD), in Lucerne, Switzerland.
Dr. Pantano received his PhD in Human Morphological Sciences from University of Bologna (Italy), conducting research in the field of Developmental Biology. After the PhD, Dr. Pantano moved to Switzerland, to conduct postdoctoral research in transcriptional regulation and signal transduction in inflammation and in cancer, at the Institute for Research in Biomedicine in Bellinzona, and at the University of Lausanne.
In 2006 Dr. Pantano moved to pharmaceutical industry joining Novartis (Basel), where he led labs developing and applying tissue based molecular assays. In 2011 Dr. Pantano joined Roche pRED (Pharma Research and Early Development) in Penzberg, Germany, to lead a team interfacing pRED Translational Research Sciences and Roche Tissue Diagnostics. In 2013 Dr. Pantano moved to Novartis Oncology Global Development as Global Correlative Science Leader; during this period Dr. Pantano led biomarker and diagnostic efforts for the ALK inhibitor ceritinib, and for immuno-oncology assets. In 2018 Dr. Pantano joined MSD as EMEAC Biomarker and Diagnostics Leader.